Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
16 February 2024 - 8:05AM
Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation
company engineering high-fidelity vaccines to protect humankind
from the consequences of bacterial diseases, announced today that
it will report financial results for the fourth quarter and full
year 2023 after market close on February 27, 2024. Company
management will host a conference call and webcast beginning at
4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial
results and provide a business update.
To participate in the conference call, please dial (800)
225-9448 (domestic) or (203) 518-9708 (international) and refer to
conference ID PCVXQ423. A live webcast of the conference call will
also be available on the investor relations page of the Vaxcyte
corporate website at www.vaxcyte.com. After the live webcast, the
event will remain archived on the Vaxcyte website for 30 days.
About Vaxcyte Vaxcyte is a vaccine innovation
company engineering high-fidelity vaccines to protect humankind
from the consequences of bacterial diseases. The Company is
developing broad-spectrum conjugate and novel protein vaccines to
prevent or treat bacterial infectious diseases. Vaxcyte’s lead
candidate, VAX-24, is a Phase 3-ready 24-valent, broad-spectrum,
carrier-sparing pneumococcal conjugate vaccine (PCV) being
developed for the prevention of invasive pneumococcal disease
(IPD). VAX-31, the Company’s next-generation 31-valent PCV, is the
broadest-spectrum PCV candidate in the clinic today. Both VAX-24
and VAX-31 are designed to improve upon the standard-of-care PCVs
for both children and adults by covering the serotypes that are
responsible for a significant portion of IPD in circulation and are
associated with high case-fatality rates, antibiotic resistance and
meningitis, while maintaining coverage of previously circulating
strains that are currently contained through continued vaccination
practice.
Vaxcyte is re-engineering the way highly complex vaccines are
made through modern synthetic techniques, including advanced
chemistry and the XpressCF™ cell-free protein synthesis platform,
exclusively licensed from Sutro Biopharma, Inc. Unlike conventional
cell-based approaches, the Company’s system for producing
difficult-to-make proteins and antigens is intended to accelerate
its ability to efficiently create and deliver high-fidelity
vaccines with enhanced immunological benefits. Vaxcyte’s pipeline
also includes VAX-A1, a prophylactic vaccine candidate designed to
prevent Group A Strep infections; VAX-PG, a therapeutic vaccine
candidate designed to slow or stop the progression of periodontal
disease; and VAX-GI, a vaccine program designed to prevent
Shigella. Vaxcyte is driven to eradicate or treat invasive
bacterial infections, which have serious and costly health
consequences when left unchecked.
For more information, visit www.vaxcyte.com.
Contacts:Janet Graesser, Vice President,
Corporate Communications and Investor RelationsVaxcyte,
Inc.917-685-8799media@vaxcyte.com
Jennifer Zibuda, Senior Director, Investor RelationsVaxcyte,
Inc.860-729-8902investors@vaxcyte.com
Vaxcyte (NASDAQ:PCVX)
Historical Stock Chart
From Apr 2024 to May 2024
Vaxcyte (NASDAQ:PCVX)
Historical Stock Chart
From May 2023 to May 2024